Candel Therapeutics (CADL) Current Assets (2020 - 2025)
Candel Therapeutics recorded quarterly Current Assets of $121.4 million in Q4 2025, up 34.68% quarter-over-quarter from $90.1 million in Q3 2025, and up 16.94% year-over-year from $103.8 million in Q4 2024.
Candel Therapeutics' Current Assets history runs 6 years deep, the most recent figure standing at $121.4 million for Q4 2025.
- In Q4 2025, Current Assets rose 16.94% year-over-year to $121.4 million; the TTM figure through Dec 2025 stood at $121.4 million (up 16.94% YoY), while the FY2025 annual figure was $121.4 million, up 16.94% from the prior year.
- Current Assets came in at $121.4 million for Q4 2025 at Candel Therapeutics, up from $90.1 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $121.4 million in Q4 2025 to a low of $18.1 million in Q3 2024.
- A 5-year average of $69.0 million and a median of $79.1 million in 2022 frame the typical range for Current Assets.
- Across the five-year window, Current Assets slumped 59.9% in 2024 and jumped 398.39% in 2025, its largest moves.
- Candel Therapeutics' Current Assets stood at $84.9 million in 2021, then decreased by 15.3% to $71.9 million in 2022, then sank by 48.85% to $36.8 million in 2023, then jumped by 182.1% to $103.8 million in 2024, then advanced by 16.94% to $121.4 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $121.4 million, $90.1 million, and $103.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 121.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121.39 Mn |
| Sep 30, 2025 | 90.13 Mn |
| Jun 30, 2025 | 103.61 Mn |
| Mar 31, 2025 | 93.15 Mn |
| Dec 31, 2024 | 103.80 Mn |
| Sep 30, 2024 | 18.09 Mn |
| Jun 30, 2024 | 22.74 Mn |
| Mar 31, 2024 | 27.14 Mn |
| Dec 31, 2023 | 36.80 Mn |
| Sep 30, 2023 | 45.10 Mn |
| Jun 30, 2023 | 53.36 Mn |
| Mar 31, 2023 | 61.88 Mn |
| Dec 31, 2022 | 71.95 Mn |
| Sep 30, 2022 | 79.07 Mn |
| Jun 30, 2022 | 87.33 Mn |
| Mar 31, 2022 | 95.65 Mn |
| Dec 31, 2021 | 84.95 Mn |
| Sep 30, 2021 | 90.95 Mn |
| Jun 30, 2021 | 24.43 Mn |
| Dec 31, 2020 | 35.15 Mn |